This working paper aims to synthesise existing research and thinking on how antimicrobials are procured and ways to improve the current purchasing system.

This note takes a quick look at the lessons learned and the existing landscape of MCM manufacturing in the context of the current pandemic response and suggests eight areas for action along with near-term recommendations to the global community to both prepare and respond to future pandemic risks. 

Countries throughout Asia are experiencing rapidly aging populations and increasing life expectancy, leading to a large and growing demand for long-term care (LTC) services. Despite the shift to providing care within communities and at home, governments are struggling to provide enough LTC to meet d...

While oral antivirals are not a substitute for vaccination, they are key to preventing severe illness, saving lives, and preserving health systems. Vaccination rates continue to be low in low-income countries; only 14 percent of the population in low-income countries has received one dose of the vac...

In the face of sudden economic shocks and natural disasters that limit the ability of economies to rapidly raise revenue, MDBs have the potential to play a leading role in crisis response to minimize the damage. One key factor in their success in this role is the speed of their financing instruments...

The COVID-19 pandemic has transformed the global vaccine manufacturing landscape, with capacity more than doubling in the past 18 months. Before the pandemic, manufacturers produced an estimated total of five billion vaccine doses each year. In 2021, manufacturers produced 12 billion doses of C...

In 2020, the Asian Development Bank (ADB) joined efforts by other multilateral development banks to rapidly scale up support to developing countries to address COVID-19. Beyond headline numbers, there has been less focus on how ADB’s support was distributed by country income group, sector, modality ...